Jawad Ahsan
Analyst · JPMorgan. Your line is now open
Thanks, Luke. We're pleased to report another strong quarter of execution. Record revenue, strong gross margins, and good cost control enabled us to bring $0.24 to the bottom line. I'm going to first talk about the VIEVU acquisition, then I'll unpack the guidance for you. After that, I'll touch upon a few housekeeping items, and then we'll go right to Q&A. So first, the VIEVU acquisition. As you can see in our shareholder letter, we paid $7.1 million upfront in cash and stock, with contingent consideration in the form of a stock-based earn-out over the next two years. This is a great deal for Axon shareholders and most importantly for the customers, who can now access the Axon network and the software features we're investing in. This deal turns a competitor into a partner and supplier and is synergistic for both companies. We only recently closed on the deal and are still working to quantify the extent of these synergies but expect there to be significant opportunities to rationalize expenses by eliminating duplicate sales efforts and combining certain aspects of our teams, both of which are based in Seattle. I’m particularly excited that this deal gives us five U.S. major city customers at about a 20% lower customer acquisition cost than we'd normally realize organically. Many people on both sides worked hard to get this deal done, and we're very pleased with the result. Next, I'd like to unpack our guidance and how we're thinking about the full-year. We're raising our revenue guidance by 2 percentage points, which reflects both the strength of Q1 and the VIEVU acquisition. In Q1, we had very strong international weapons revenue, which we do not expect to benefit from in Q2. We expect Q2 weapons revenue to grow about 7% to 10% year-over-year. So, as you think about the timing of how revenue will flow through the P&L and you rebalance your estimates for the full-year, we expect Q2 revenue to be down sequentially from Q1. Turning to operating margin guidance. We did a great job on costs in Q1, and as Rick said, our new culture around driving leverage is here to stay. We were pleased to deliver a 13% operating margin in Q1, but we're still investing for growth and we have more investments to make this year. As you think about VIEVU's impact on operating margins, it's really in two buckets. First, some of VIEVU's larger contracts were priced at a level below what Axon would've bid, and we are going to honor those customer contracts. As a result, we'll see some gross margin pressure in the Software & Sensors segment as we deliver on those contracts. Second, we expect some nonrecurring transaction and integration expenses. What we feel great about is that, thanks to our rigorous cost control, we can absorb those contracts and still maintain our 2018 guidance for operating margin expansion. To be clear, this implies an operating margin of 6.8% to 7.8%, excluding onetime transaction costs, consistent with what we told you in February. Onetime transaction integration costs should amount to about 50 basis points of margin for the full-year, with the majority hitting in Q2. So, as we look at the balance of the year, we expect Q2 to be the low point in operating margin and build from there. This reflects an expected increase in OpEx in the second quarter, driven by focused investments we're making in our new product pipeline, VIEVU operating expenses and onetime acquisition costs. Also, because we don't want there to be any surprises, our guidance commentary excludes the impact from stock-based compensation associated with Rick Smith's new 10-year, no-salary, equity-based compensation plan. Our shareholders will vote on that plan on May 24, and the board and myself recommend they vote for that plan. We think it's a great plan for Axon and for shareholders. Rick hasn't gotten a paycheck in the past few months, and he won't get one for another 10 years. Under this plan, Rick will only get paid if we deliver outsized growth in revenue and EBITDA and corresponding shareholder returns. We expect to incur some noncash expenses associated with Rick's stock plan, and the amount will be determined by the stock price at the time of the vote. We'll make sure to give visibility around that on our next earnings call, and as a reminder, our non-GAAP earnings now exclude stock-based compensation expenses, so adjusted EPS won't be affected. To wrap up our margin commentary, even with absorbing VIEVU's contracts and operating costs, we're still on track to hit our operating margin guidance for the full-year. Next, I want to address the portion of our shareholder letter that talks about TASER Weapons growth. We've historically talked about TASER Weapons having four primary growth drivers. Those are: selling more to domestic law enforcement, expanding internationally, shortening upgrade cycles from eight to five years and offering more features and smarter weapons. We still have a long runway in law enforcement, but we're also seeing increased demand for the TASER weapon outside of law enforcement. We're getting orders from private security, campus security, U.S. federal agencies and several others. We broke that down for you in our shareholder letter. This is not a disclosure that we intend to make going forward. We don't plan to keep breaking out TASER Weapons sales by geography and customer segment, but we did want to communicate the source of our confidence in a growing TAM, which is helping to drive strength in that segment. Finally, some housekeeping items for those of you who've followed us for a while. We're updating several of our descriptors in the Software & Sensors segment. There are three minor changes. The first change is that we are now giving Software & Sensors backlog rather than future contracted revenue, so that our metrics are more closely aligned with the backlog numbers we report in our 10-Q. As of March 31, 2018, we had approximately $570 million of Software & Sensors backlog, which is a slightly different calculation than the former future contracted revenue, though the numbers were pretty similar. The backlog figure includes both recognized contract liabilities, as well as amounts that will be invoiced and recognized in future periods. The second change is that we will now be referring to annual recurring service revenue as Software & Sensors annual recurring revenue, and that includes cloud-based software, data storage and warranty, same as above. The third change has to do with how we report our Software & Services revenue. Same as always, product roughly aligns with hardware revenue and service aligns with cloud-based software revenue. And so, starting this quarter, we've begun referring to Software & Sensors service revenue as Axon Cloud revenue, which is a better descriptor because that revenue bucket includes all the items tied to our cloud-based software platform, Evidence.com, and the professional services and data storage that support our cloud-based software offering. Mirroring that, when we talk about the product bucket, we'll be calling that Sensors and Other, because it encapsulates revenue related to our on-officer body cameras, Axon Fleet hardware, Signal Sidearm, TASER Cams, and other hardware plus warranty revenues. What this does is isolate our Axon Cloud revenue so that the investment community can track this growing and increasingly important category. And with that, operator, we'd like to open the call for questions.